Articles tagged with: research

The benefits of prompt HIV treatment

published: March, 23, 2016 Written by // Guest Authors - Revolving Door Categories // Treatment Guidelines -including when to start, Research, Health, Revolving Door, Treatment, Guest Authors

Aidsmap reports yet more evidence that starting testament early produces better outcomes including quality of life and “should provide reassurance to people who worry about HIV medications being ‘strong’, ‘toxic’ or causing more harm than good.”

The benefits of prompt HIV treatment

This article previously appeared in aidsmap's HIV Update here. Further findings from START, a major study which aimed to identify the benefits and harms of beginning HIV treatment at a high CD4 cell count, have recently been released. These findings concern cancer, heart disease and quality of life.  This study enrolled 4685 men and women with HIV who had never taken HIV treatment, were in generally good health and had a CD4 cell count over 500 cells/mm3. Based on random allocation, half t

After diagnosis: what happens next?

published: March, 09, 2016 Written by // Guest Authors - Revolving Door Categories // Gay Men, Research, Sexual Health, Health, Revolving Door, Guest Authors, Living with HIV, Opinion Pieces, Population Specific , Sex and Sexuality

Researcher Sarah Chown writes about understanding the impact of HIV among recently diagnosed gay men in Vancouver

After diagnosis: what happens next?

Background In April 2009, the CIHR Team for the Study of Acute HIV Infection in Gay Men helped to bring a new HIV testing technology, called the early HIV test, to Vancouver. The early HIV test can diagnose HIV during the acute infection period, a time when most HIV tests cannot detect infection due to limitations in testing technology. The acute infection period refers to the initial weeks and months of HIV infection during which there are very high amounts of HIV in the body. The early HIV

Starting HIV treatment at first clinic visit improves outcomes in African study

published: March, 04, 2016 Written by // Guest Authors - Revolving Door Categories // Treatment Guidelines -including when to start, Newly Diagnosed, Research, Health, Revolving Door, International , Treatment, Guest Authors, Living with HIV, Population Specific

What once seemed like a rash idea is becoming validated as more research suggests same day treatment initiation works best and is well accepted

Starting HIV treatment at first clinic visit improves outcomes in African study

This article by Liz Highleyman produced in collaboration with hivandhepatitis.com first appeared on aidsmap.com here.   A programme to accelerate the process of HIV diagnosis, preparation and starting antiretroviral therapy (ART) in South Africa led to a higher proportion of people initiating treatment and better health outcomes, according to results from the RapIT trial presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016) taking place this week in Boston, US

Resistance to Tenofovir

published: February, 12, 2016 Written by // Guest Authors - Revolving Door Categories // Research, Health, Revolving Door, Treatment, Guest Authors, Living with HIV

Aidsmap reports “A significant proportion of people who experienced failure of HIV treatment have resistance to tenofovir, one of the key drugs used in HIV treatment.”

Resistance to Tenofovir

A significant proportion of people who experienced failure of HIV treatment have resistance to tenofovir, one of the key drugs used in HIV treatment. Tenofovir is a component of the tablets Viread, Truvada, Atripla, Eviplera and Stribild.  This story has been widely reported in the mainstream media, but not always accurately. Media reports may have given the impression that, in some regions, half of all people with HIV have resistance. In fact, the study only looked at people who had taken t

Have drug resistance issues and on a complicated regime?

Aidsmap reports nucleoside drugs can be left out of combinations for people with lots of drug resistance.

Have drug resistance issues and on a complicated regime?

 This article from aidsmap.com first appeared here.  With modern anti-HIV drugs, most people are able to find a safe and effective combination of drugs which they are able to take for several years.  Nonetheless a few people who have had problems with treatment in the past may have resistance to several classes of anti-HIV drugs. When changing treatment, choosing a new, effective treatment regimen can be tricky. The aim is to put together a combination that includes two or preferably thre

The real sex lives of HIV-positive gay men

published: December, 02, 2015 Written by // Guest Authors - Revolving Door Categories // Gay Men, Research, Revolving Door, International , Guest Authors, Living with HIV, Population Specific , Sex and Sexuality

What do we know about the kinds of sex HIV-positive gay men are having? The UK FS Magazine’s “Big Gay Sex Survey” provides some of the answers.

The real sex lives of HIV-positive gay men

This article by Ian Howley @ianhowley first appeared in the UJ’s FS Magazine, a publication of GMFA, here.  Most HIV-positive gay men will tell you living with HIV can be frustrating at times, not because of the condition but because of other people’s attitudes. In our ‘Big Gay Sex Survey’, out of the 3,141 men who took part 9% said they were living with HIV. So we looked at the sex lives of the men who know they have HIV to see the differences, if any, between HIV-positive men and

Towards a Canadian vision for new HIV prevention options

published: December, 01, 2015 Categories // Activism, As Prevention , Sexual Health, Health, Treatment, Opinion Pieces

Marc-André LeBlanc says “we have not yet come together to articulate a vision for PrEP and the preventive effect of treatment for our community." Here’s his.

Towards a Canadian vision for new HIV prevention options

This article was adapted from comments delivered as part of a panel presentation for “PrEPared: A Community Health Forum”, organized by AIDS Community Care Montreal (ACCM) in November 2015.  In a recent TED talk on PrEP and rectal microbicides, Will Nutland from the London School of Hygiene and Tropical Medicine in the UK reminded us of the ending to the 1989 movie Longtime Companion, where the surviving characters walk along a beach and wonder what the end of AIDS will look like. They i

A groundbreaking year in HIV treatment and prevention

published: November, 23, 2015 Written by // CATIE - HIV and Hep C Info Resource Categories // As Prevention , CATIE, Treatment Guidelines -including when to start, Research, CATIE - HIV and Hep C Info Resource, Health, International , Treatment, Living with HIV, Opinion Pieces

CATIE says: “Evidence that has been building over the past few years about the treatment and prevention of HIV is so significant, some people are calling it revolutionary. The question for the world is: When will we put it into practice?”

A groundbreaking year in HIV treatment and prevention

This article previously appeared on the CATIE website here.   Une version française est disponible ici.  It’s historic. It’s inspiring. Evidence that has been building over the past few years about the treatment and prevention of HIV is so significant, some people are calling it revolutionary. Showcased at this year’s International AIDS Society (IAS) conference in Vancouver, our new information forever changes the prospects of health for those living with HIV, their partners and

One cause, one community, together for one unique night

published: November, 17, 2015 Written by // Guest Authors - Revolving Door Categories // Community Events, Fundraisers, Events, Revolving Door, Guest Authors

CANFAR announces their Toronto fundraiser Bloor Street Entertains, Canada’s largest fundraiser in support of HIV and AIDS research

One cause, one community, together for one unique night

On Wednesday, November 25th, Torontonians will come together to dine in style in support of Canadian AIDS Research.  The Canadian Foundation for AIDS Research’s (CANFAR) is hosting their annual event, Bloor Street Entertains.  Now in its 19th year guests will enjoy a culinary experience from Toronto’s top chefs in some of the city’s most exquisite boutiques, galleries and museums along the Bloor-Yorkville corridor. This unique and unforgettable evening begins with a seated dinner in

Researchers experimenting with HIV treatment using long-acting injections

published: November, 16, 2015 Written by // Guest Authors - Revolving Door Categories // Current Affairs, Research, Health, Revolving Door, Treatment, Guest Authors

HIVandHepaittis.com reports long-acting injectable Cabotegravir + Rilpivirine maintains HIV suppression for 32 weeks

Researchers experimenting with HIV treatment using long-acting injections

This article by Liz Highleyman  first appeared in HIVandHepatitis.com here.  A combination of two long-acting injectable antiretrovirals -- ViiV Healthcare's experimental integrase inhibitor cabotegravir and Janssen's NNRTI rilpivirine -- given once every 4 or 8 weeks maintained viral suppression as well as a standard oral regimen and appears safe and well-tolerated, the companies announced this week. These findings from the Phase 2b LATTE 2 trial follow earlier reports from the original LA

<<  1 [23 4 5 6  >>